The decrease in ferroptosis and lipid ROS levels induced by TNF could be eliminated by adalimumab, a fully human monoclonal TNF antibody (Fig. 5e, f) that has been approved for the treatment of RA, juvenile idiopathic arthritis, ankylosing spondylitis, and inflammatory bowel disease27. Here, TNF is linked to rheumatoid arthritis.